News|Articles|November 4, 2024
Best Practices, Strategies & Use of Novel Biological Responses for Robust Cell-Based Potency Assays
Author(s)Catalent
Cell-based assays (CBAs) are key tools for evaluating the potency of new biologic drugs. Catalent’s transcription-based bioassay simplifies and empowers the testing of new biologics.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Trending on Pharmaceutical Technology
1
FDA Launches PreCheck Pilot Program to Bolster Domestic Drug Manufacturing
2
Bristol Myers Squibb and Johnson & Johnson Launch Educational Program for Thromboembolic R&D
3
Cellares Scales IDMO Model for Gene-Edited Stem Cells Therapies
4
Women in STEM: Cultivating Scientific Confidence
5